Inhibition of vascular endothelial growth factor with shRNA in chondrocytes ameliorates osteoarthritis
- 10 May 2016
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 94 (7) , 787-798
Abstract
Osteoarthritis (OA) is a chronic, incurable and destructive joint disease that is characterized by chondrocyte hypertrophy and cartilage degradation. AngioKeywords
Funding Information
- National Health and Medical Research Council of Australia (APP1032738)
- Common Good (MS2012-25)
This publication has 39 references indexed in Scilit:
- Injection of vascular endothelial growth factor into knee joints induces osteoarthritis in miceOsteoarthritis and Cartilage, 2013
- Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiationJournal of Clinical Investigation, 2012
- Runx2 contributes to murine Col10a1 gene regulation through direct interaction with its cis-enhancerJournal of Bone and Mineral Research, 2011
- Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAsCancer Gene Therapy, 2010
- Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritisRheumatology, 2010
- Identification and Functional Characterization of ERK/MAPK Phosphorylation Sites in the Runx2 Transcription FactorJournal of Biological Chemistry, 2009
- Blocking vascular endothelial growth factor with soluble Flt‐1 improves the chondrogenic potential of mouse skeletal muscle–derived stem cellsArthritis & Rheumatism, 2008
- Chondromodulin-I and tenomodulin are differentially expressed in the avascular mesenchyme during mouse and chick developmentCell and tissue research, 2008
- Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritisAnnals of the Rheumatic Diseases, 2007
- Osteoarthritis gene therapyGene Therapy, 2004